Clinical Trial Update: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven [NA]

View source ↗

Summary

This clinical trial update reports on the plasma dosing of venetoclax in AML patients treated with azacitidine plus venetoclax. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Acute Myeloid Leukemia | NA | Status: COMPLETED